Search results for "Parkinson’s Disease."

showing 10 items of 88 documents

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

Movement disorders/Parkinson’s diseaseDrug CarriersPolymersSurface PropertiesReviewsBrainAlzheimer's diseaseMultiple sclerosisDrug Delivery SystemsMovement disorders/Parkinson's diseaseSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoLiposomesNeuropsychopharmacology.AnimalsHumansNanoparticlesMultiple sclerosiParticle SizeNeuropsychopharmacologyAlzheimer’s diseaseMicellesCentral Nervous System Agents
researchProduct

PGC-1α: a master gene that is hard to master

2012

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…

medicine.medical_specialtyModels NeurologicalSettore BIO/11 - Biologia MolecolareRNA-binding proteinBiologyMitochondrionSettore BIO/09 - FisiologiaMiceCellular and Molecular NeuroscienceHeat shock proteinInternal medicinemedicineAnimalsHomeostasisHumansReceptorMolecular BiologyTranscription factorHeat-Shock ProteinsMice KnockoutPharmacologyPGC-1α Mitochondria Dopaminergic neurons Transgenic animal Adenovirus Parkinson’s diseaseDopaminergic NeuronsDopaminergicRNA-Binding ProteinsParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaEndocrinologyCell metabolismNerve DegenerationTrans-ActivatorsMolecular MedicineNeuroscienceHomeostasisTranscription FactorsCellular and Molecular Life Sciences
researchProduct

Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed …

2022

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor impairments and it is correlated with loss of bone mineral density. This study aimed to analyze the effects of resistance training on bone metabolism, systemic homeostasis, body composition, and physical performance in people with PD. Thirteen subjects (age 64.83 ± 5.70) with PD diagnosis were recruited. Participants performed neuromuscular tests, body composition assessment, and blood sample analysis at baseline, and after an 11 weeks-training period. Each training session lasted 90 min, three times a week. The participants had significant improvements in the timed up and go (p < 0.01), sit to stand (p < …

Health Toxicology and MutagenesisOsteocalcinPublic Health Environmental and Occupational Healthphysical activityResistance TrainingParkinson DiseasePilot ProjectsMiddle AgedPhysical Functional Performanceosteogenesiphysical activity; neurodegenerative disease; resistance training; bone resorption; osteogenesis; osteoporosis; Parkinson’s diseaseneurodegenerative diseaseParkinson’s diseaseBody CompositionHumansHomeostasisosteoporosiCalciumVitamin Dbone resorptionAgedInternational Journal of Environmental Research and Public Health; Volume 19; Issue 20; Pages: 13022
researchProduct

Therapeutic Benefits of Music-Based Synchronous Finger Tapping In Parkinson’s Disease – an fNIRS Study Protocol for Randomized Controlled Trial in Da…

2020

Abstract Background: Music therapy improves neuronal activity and connectivity of healthy persons and patients with clinical symptoms of neurological diseases like Parkinson’s disease, Alzheimer’s Disease, and Major Depression. Despite the plethora of publications that have reported the positive effects of music interventions, little is known about how music improves neuronal activity and connectivity in afflicted patients.Methods: For patients suffering from Parkinson’s disease (PD), we propose a daily 25-minute music-based synchronous finger tapping (SFT) intervention for 8-weeks. Eligible participants with PD are split into two groups: an intervention group and a control arm. In addition…

explicit and implicit timingmusic therapymusiikkifNIRSmusiikkiterapiaParkinsonin tautineurodegeneratiiviset sairaudethermosolutmotor-controlaivokuorirandomized controlled trialshoitomenetelmätParkinson’s diseasesynchronous finger tapping
researchProduct

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

G2019S Variation in LRRK2: An Ideal Model for the Study of Parkinson's Disease?

2019

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and has plagued humans for more than 200 years. The etiology and detailed pathogenesis of PD is unclear, but is currently believed to be the result of the interaction between genetic and environmental factors. Studies have found that PD patients with the LRRK2:G2019S variation have the typical clinical manifestations of PD, which may be familial or sporadic, and have age-dependent pathogenic characteristics. Therefore, the LRRK2:G2019S variation may be an ideal model to study the interaction of multiple factors such as genetic, environmental and natural aging factors in PD in the future. This article reviewed the …

Parkinson's diseaseNatural agingDiseaseReviewBioinformatics050105 experimental psychologylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicineG2019s mutationG2019S mutationmedicine0501 psychology and cognitive scienceslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological Psychiatrybusiness.industrydisease modelpathogenesis05 social sciencesLRRK2medicine.diseaseLRRK2nervous system diseasesPsychiatry and Mental healthNeuropsychology and Physiological PsychologyMultiple factorsVariation (linguistics)NeurologyEtiologyParkinson’s diseasebusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in human neuroscience
researchProduct

Development of a Parkinson’s disease specific falls questionnaire

2020

Abstract Background Falls are a major health burden for older adults with Parkinson’s disease (PD), but there is currently no reliable questionnaire to capture the circumstances and consequences of falls in older adults with PD. This study aimed to develop a PD-specific falls questionnaire and to evaluate its test-retest reliability in older adults with PD. Methods A novel PD-specific falls questionnaire (PDF-Q) was developed in two modes (online and paper-based version) and used to assess falls and near-falls events over the past 12-months. Questions were agreed upon by an expert group, with the domains based on previous falls-related questionnaires. The questions included the number and c…

medicine.medical_specialtykyselytutkimusFalls in older adultsParkinsonin tautinear-fallsSurveys and QuestionnairesNear-fallsfallsMedicineHumansAgedreliabiliteettikaatuminenreliabilityMedical treatmentGeriatrics gerontologybusiness.industryQuestionnaireResearchquestionnaireRC952-954.6Reproducibility of ResultsParkinson DiseaseReliabilityExpert groupGeriatricsPhysical therapyParkinson’s diseaseFallsGeriatrics and GerontologybusinessikääntyneetBMC Geriatrics
researchProduct

Focus on the Small GTPase Rab1: A Key Player in the Pathogenesis of Parkinson’s Disease

2021

Parkinson’s disease (PD) is the second most frequent neurodegenerative disease. It is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of large aggregates in the survival neurons called Lewy bodies, which mainly contain α-synuclein (α-syn). The cause of cell death is not known but could be due to mitochondrial dysfunction, protein homeostasis failure, and alterations in the secretory/endolysosomal/autophagic pathways. Survival nigral neurons overexpress the small GTPase Rab1. This protein is considered a housekeeping Rab that is necessary to support the secretory pathway, the maintenance of the Golgi complex structure, and the regulation of macroau…

autophagyParkinson's diseaseQH301-705.5Substantia nigraReviewBiologyCatalysisInorganic Chemistryα-synucleinmedicineAnimalsHumansSmall GTPaseBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopySecretory pathwayRab1GTPasesOrganic ChemistryNeurodegenerationDopaminergicRAB1Parkinson DiseaseLRRK2General Medicinemedicine.diseaseLRRK2Computer Science Applicationssecretory pathwayrab1 GTP-Binding ProteinsChemistrynervous systemParkinson’s diseaseNeuroscienceGolgi fragmentationInternational Journal of Molecular Sciences
researchProduct

Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease.

2003

High levels of neuropeptide Y (NPY) are found in basal ganglia where it is co-localised with somatostatin (SOM) and nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH/d) in a population of striatal GABA containing interneurones. Although alterations occur in the levels of various neuropeptides in basal ganglia in Parkinson’s disease (PD), it is not known whether NPY is affected. Using in situ hybridisation immunohistochemistry, we have examined the distribution of NPY mRNA in the caudate nucleus, putamen and nucleus accumbens of normal individuals and patients with PD. NPY mRNA was weakly expressed in the caudate nucleus, putamen and nucleus accumbens in normal individuals with a…

Malemedicine.medical_specialtyIn situ hybridisationPopulationCaudate nucleusNeuropeptideStriatumBiologyNucleus accumbensNucleus AccumbensStriatumCellular and Molecular NeuroscienceNeuropeptide Y (NPY)InterneuronsInternal medicinemental disordersBasal gangliamedicineHumansNeuropeptide YRNA MessengereducationMolecular BiologyAgededucation.field_of_studyPutamenPutamenParkinson DiseaseMiddle AgedNeuropeptide Y receptorhumanitiesCorpus StriatumEndocrinologynervous systemGene Expression RegulationParkinson’s diseaseSettore BIO/14 - FarmacologiaFemaleCaudate NucleusBrain research. Molecular brain research
researchProduct

Sleep quality in caregivers of patients with Alzheimer’s disease and Parkinson’s disease and its relationship to quality of life

2012

ABSTRACTBackground: Knowledge about sleep complaints of caregivers of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) is limited, and we lack information about the relationship between caregivers’ sleep problems and their quality of life (QoL).Methods: We evaluated subjective sleep quality and its relationship to QoL in a group of 80 caregivers of patients with AD (ADCG, n = 40) and PD (PDCG, n = 40), and in 150 controls. Information about night-time complaints was collected using the Pittsburgh Sleep Quality Index (PSQI). QoL was measured using the McGill QoL Questionnaire.Results: Eighteen ADCG (45%), 22 PDCG (55%), and 45 (30%) controls reported poor sleep quality. Me…

MaleSleep Wake DisordersCoping (psychology)medicine.medical_specialtyParkinson's diseaseDiseaseSleep Wake DisordersSeverity of Illness IndexPittsburgh Sleep Quality IndexCost of IllnessAlzheimer DiseaseSickness Impact ProfileSurveys and QuestionnairesSeverity of illnessMedicineHumansAgedAged 80 and overAlzheimer’s disease Parkinson’s disease neurodegenerative disorders caregivers sleep depression quality of lifebusiness.industryDepressionParkinson DiseaseMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologySleep deprivationCaregiversItalyPhysical therapyQuality of LifeRegression AnalysisSleep DeprivationFemaleSettore MED/26 - NeurologiaSelf ReportGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasebusinessGerontologyStress Psychological
researchProduct